BMY Q4 2017 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q4 2017 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$5.4B+3.9% YoY

Gross Profit

$3.8B68.9% margin

Operating Income

$1.0B18.9% margin

Net Income

-$2.3B-42.7% margin

EPS (Diluted)

$-1.42

QoQ Revenue Growth

+3.7%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$863M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$33.6B

Total Liabilities

$21.7B

Stockholders' Equity

$11.7B

Cash & Equivalents

$5.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.4B	$5.2B	+3.9%
Gross Profit	$3.8B	$3.7B	+2.3%
Operating Income	$1.0B	$997M	+3.2%
Net Income	-$2.3B	$894M	-360.4%

Revenue Segments

Eliquis

$1.4B25%

Opdivo

$1.4B25%

Orencia

$662M12%

Mature Products And All Other

$595M11%

Sprycel

$527M10%

Yervoy

$269M5%

Baraclude

$233M4%

Sustiva Franchise

$174M3%

Reyataz

$143M3%

Empliciti

$63M1%

Hepatitis C Portfolio

$59M1%